# Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

> **NCT01110200** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 639 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** ADVAIR DISKUS 250/50 mg BID
- **DRUG:** SEREVENT 50 mcg BID

## Key facts

- **NCT ID:** NCT01110200
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-30
- **Primary completion:** 2012-04-01
- **Final completion:** 2012-05-08
- **Target enrollment:** 639 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110200, "Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01110200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*